HRTX Heron Therapeutics Inc

Price (delayed)

$18.08

Market cap

$1.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.5

Enterprise value

$1.57B

Sector: Healthcare
Industry: Biotechnology

Highlights

The gross margin has grown by 2.4% YoY
The quick ratio has contracted by 45% YoY and by 18% from the previous quarter
The equity has declined by 41% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
91.4M
Market cap
$1.65B
Enterprise value
$1.57B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.95
Price to sales (P/S)
18.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.73
Earnings
Revenue
$88.64M
EBIT
-$229.01M
EBITDA
-$226.16M
Free cash flow
-$191.63M
Per share
EPS
-$2.5
Free cash flow per share
-$2.11
Book value per share
$2.6
Revenue per share
$0.98
TBVPS
$3.89
Balance sheet
Total assets
$353.56M
Total liabilities
$117.06M
Debt
$24.61M
Equity
$236.49M
Working capital
$211.69M
Liquidity
Debt to equity
0.1
Current ratio
3.07
Quick ratio
2.44
Net debt/EBITDA
0.36
Margins
EBITDA margin
-255.2%
Gross margin
59.2%
Net margin
-256.4%
Operating margin
-257.4%
Efficiency
Return on assets
-54.9%
Return on equity
-75.6%
Return on invested capital
-93.3%
Return on capital employed
-91.2%
Return on sales
-258.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
0.17%
1 week
-4.84%
1 month
2.96%
1 year
-2.11%
YTD
-14.6%
QTD
-14.6%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$88.64M
Gross profit
$52.45M
Operating income
-$228.16M
Net income
-$227.28M
Gross margin
59.2%
Net margin
-256.4%
The net margin has dropped by 83% year-on-year and by 19% since the previous quarter
HRTX's operating margin has dropped by 78% year-on-year and by 17% since the previous quarter
HRTX's revenue is down by 39% year-on-year and by 14% since the previous quarter
HRTX's gross profit is down by 38% year-on-year and by 13% since the previous quarter

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
6.95
P/S
18.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.73
The equity has declined by 41% year-on-year and by 15% since the previous quarter
The P/B is 39% higher than the last 4 quarters average of 5.0 but 28% lower than the 5-year quarterly average of 9.6
HRTX's price to sales (P/S) is 67% less than its 5-year quarterly average of 55.9 but 40% more than its last 4 quarters average of 13.2
HRTX's revenue is down by 39% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has shrunk by 79% YoY and by 17% QoQ
The ROIC has contracted by 37% YoY and by 20% from the previous quarter
Heron Therapeutics's ROE has decreased by 23% YoY and by 16% from the previous quarter
HRTX's ROA is down by 18% YoY and by 12% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
The quick ratio has contracted by 45% YoY and by 18% from the previous quarter
The current ratio has contracted by 38% YoY and by 15% from the previous quarter
The debt is 90% smaller than the equity
The debt to equity has soared by 100% year-on-year and by 11% since the previous quarter
The equity has declined by 41% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.